Outcomes After Switching to Faricimab in Neovascular Age-Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry

2025/07/27 by Hunt, Adrian, Hashimoto, Yohei, Young, Stephanie +7
Medicine · #610 Medicine &amp #AMD #Faricimab #Ocular Diseases and Behçet’s Syndrome #Retinal Diseases and Treatments #Retinal Imaging and Analysis #health #macula #neovascular #switching

paper · doi:10.5167/uzh-281175

openalex publication_date 2025/07/27 · openalex created_date 2025/12/11 · openalex updated_date 2026/07/28

Abstract

Background: We aimed to describe 1-year outcomes of eyes switched to faricimab from first-generation vascular endothelial growth factor (VEGF) inhibitors for neovascular age-related macular degeneration (nAMD) in routine care. Methods: Multicentre, observational study of 383 eyes tracked in the Fight Retinal Blindness! registry switched to faricimab from aflibercept 2 mg, ranibizumab, or bevacizumab between 1st January-1st August 2023 in Australia. Conclusions: We found that faricimab inactivated a significant proportion of CNV lesions that had been active using 1st generation VEGF inhibitors, with a significant extension of the treatment interval. A small reduction in VA occurred in switchers and eyes not switched through the same period.

Related

• One-Year Outcomes after Switching to Faricimab in Eyes with Pretreated Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report
• Twelve-Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry
• Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF
• Treatment Regimens with Ranibizumab in Neovascular Age-Related Macular Degeneration: Real-World Results from the PACIFIC Study
• Efficacy of Aflibercept 8 mg in Pretreated Age-Related Macular Degeneration